<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100303003485N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-20</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>The effect of sildenafil citrate on cesarean section during labor</public_title>
      <acronym>Sildenafil citrate</acronym>
      <scientific_title>The effect of sildenafil citrate on fetal distress during labor and cesarean section - a double-blind clinical trial with placebo</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>104</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64428</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: 208 pregnant mothers referred to Al-Zahra Hospital in Rasht are randomly divided into 2 groups of 104 (intervention and control). Group 1 (intervention) is called A and group 2 (control) is called B. Random blocking will be done in such a way that numbers are assigned to the research units in order. Then there is a table with 47 rows called blocks and each block will have 4 parts and each part is named A and B, will be considered. In the next step, the numbers are placed in each house in order. After all the numbers are placed in the blocks, People who had a number in house A, Package with code A and people who had a number in house B, They will receive a package with code B. Concealment is done using the sealed envelope method. An online randomization service was used to generate the list.
https://www.sealedenvelope.com/simple-randomiser/v1/lists, Blinding description: The treatment group of each patient(The intervention group receiving sildenafil capsules and the control group receiving placebo capsules) will be determined only after randomization. This project will be carried out by a group of medical experts and all people will be blind (participants, Principal investigator, Health care personnel who are responsible for taking care of patients, Responsible for data collection, those who evaluate the outcome), Except for one specialist doctor who is independent from the research team, who prescribes the assigned codes for each of the pregnant mothers who refer to Al-Zahra Rasht Hospital. Also, each group of patients (intervention and control) will be treated in a separate place and are not related to each other.</study_design>
      <phase>3</phase>
      <hc_freetext>Fetal distress in pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: a group of 104 people who received a package containing three oral capsules of sildenafil 50 mg brand Marham Darou (SDF),  prepared by the pharmacy, up to a maximum of 3 doses every 6 hours. The first dose of sildenafil is given when the participant enters the labor ward for delivery (Spontaneous birth with dilatation of less than 4 cm, pregnant women who have cervical rip and induction has started for them and have effective contractions or induction of labor with oxytocin or rupture of the water sac) and the patient's blood pressure is measured every 15-30 minutes. Fetal heart rate monitoring is done and pregnancy care is ensured in both study groups. Intervention 2: Control group: a group of 104 people who received a package containing three oral capsules of Mehram Daro brand prepared by the pharmacy, receive up to 3 doses every 6 hours. The first placebo dose is given when the participant enters the labor ward for delivery(Spontaneous birth with dilatation of less than 4 cm, pregnant women who have cervical rip and induction has started for them and have effective contractions or induction of labor with oxytocin or rupture of the water sac) and the patient's blood pressure is measured every 15-30 minutes. Fetal heart rate monitoring is done and pregnancy care is ensured in both study groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azadeh mahmoudi eisa abadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>54839- 41446</zip>
        <telephone>+98 13 3336 9224</telephone>
        <email>Azade264@gmail.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Forozan Milani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital, Namjoo Ave., Rasht, Guilan, IRAN</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>54839 -41446</zip>
        <telephone>+98 13 3336 9224</telephone>
        <email>forozanmilani@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18-40 years
Single pregnancy
Term pregnancy (37-41 weeks)
Normal fetal structure and without any anomalies
Cephalic presentation
Estimated weight above 2500 grams
Without CPD
Candidate for normal vaginal delivery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Drug reaction to Sildenafil
Fetal anomalies
Metabolic disorder
Cardiac disorders
Renal disorders
Visual disorders
Liver anomalies
Previous cesarean
Preeclampsia
HTN
Alcohol
Taking medications Nitrate
α-blocker</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: a group of 104 people who received a package containing three oral capsules of sildenafil 50 mg brand Marham Darou (SDF),  prepared by the pharmacy, up to a maximum of 3 doses every 6 hours. The first dose of sildenafil is given when the participant enters the labor ward for delivery (Spontaneous birth with dilatation of less than 4 cm, pregnant women who have cervical rip and induction has started for them and have effective contractions or induction of labor with oxytocin or rupture of the water sac) and the patient's blood pressure is measured every 15-30 minutes. Fetal heart rate monitoring is done and pregnancy care is ensured in both study groups.</i_keyword>
      <i_keyword>Control group: a group of 104 people who received a package containing three oral capsules of Mehram Daro brand prepared by the pharmacy, receive up to 3 doses every 6 hours. The first placebo dose is given when the participant enters the labor ward for delivery(Spontaneous birth with dilatation of less than 4 cm, pregnant women who have cervical rip and induction has started for them and have effective contractions or induction of labor with oxytocin or rupture of the water sac) and the patient's blood pressure is measured every 15-30 minutes. Fetal heart rate monitoring is done and pregnancy care is ensured in both study groups.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Need for cesarean section. Timepoint: The first dose of sildenafil or placebo when the participant is in the active phase of labor. For delivery, she enters the labor department and is given. Sildenafil is given orally 50 mg every 8 hours for a maximum of 3 doses. Method of measurement: The patient's blood pressure is measured every 15-30 minutes. Fetal heart rate is monitored.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Type of delivery. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Cesarean section indication. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Labor duration. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Abnormal bleeding during and after delivery. Timepoint: Until after delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Meconium excretion. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Need for fetal blood sampling. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Fetal  distress. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Birth weight. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Neonatal sex. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Apgar scores. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Umbilical artery pH. Timepoint: Until every stage of childbirth. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Need for neonatal resuscitation. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Length of time in neonatal intensive care unit. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Seizures. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Neonatal encephalopathy. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
      <sec_outcome>Fetal and infant death. Timepoint: After delivery. Method of measurement: Will be recorded in the checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-01</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Research vice-chancellorship Building, in front of 17-Shahrivar Hospital, ShahidSiadati St., Namjoo Ave., Rasht, Guilan, IRAN Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
